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The nonmotor symptoms (NMSs) of Parkinson’s disease
(PD) have received a lot of attention in the last few years.
Despite this fact, they have still been underrecognized and
undertreated [1, 2]. NMS may include cognitive problems,
apathy, depression, anxiety, hallucinations, and psychosis
as well as sleep disorders, fatigue, autonomic dysfunction,
sensory problems, and pain [1]. Since these symptoms sub-
stantially contribute to patients’ quality of life and are a
frequentcauseofhospitalizationandinstitutionalization,the
NMSs and their management have been recognized by the
UK National Institute for Clinical Excellence as an important
unmet need in PD [3]. Besides dopamine and Lewy-type
pathology involving both striatal and extrastriatal brain
regions, deﬁcits in other neurotransmitter systems and/or
other types of brain pathologies seem to play a key role in
the pathogenesis of NMS in PD [4–6].
It has been clearly shown that dopaminergic treatment
improves motor symptoms and the quality of life in patients
with PD. However, it only partly improves some features
of the NMS, and it is not free from nonmotor side eﬀects
such as hallucinations and other psychotic symptoms, irrita-
bility, sleep attacks, and impulse control disorders. Further-
more, one study found that the patients who survived at
20 years from PD diagnosis suﬀered mainly from the non-
dopaminergicsymptomsincludingfalls,choking,dysarthria,
but also dementia, visual hallucinations, daytime som-
nolence, symptomatic postural hypotension, and urinary
incontinence [7]. Therefore, the management of these non-
dopaminergic symptoms is a priority for research in the near
future.
In addition to pharmacotherapy, high-frequency deep
brain stimulation of the subthalamic nucleus (STN DBS)
is a powerful surgical treatment in well-selected candidates
with advanced PD. STN DBS leads to improvements in
dopaminergic drug-sensitive symptoms and reductions in
subsequent drug dose and dyskinesias [8]. Although quality
of life improves substantially, the procedure cannot be
recommended for the treatment of NMS, and it may even
cause speciﬁc cognitive side eﬀects and may increase the risk
for suicide. Skilled speech and physical therapy with cueing
to improve gait, cognitive therapy to improve transfers,
exercisestoimprovebalance,andtrainingtobuildupmuscle
power and increase joint mobility are eﬃcacious. Regular
physical and mental exercise is therefore recommended for
a l lP Dp a t i e n t s[ 9].
As outlined above, multidisciplinary approach including
both pharmacological and nonpharmacological treatment
of PD is essential; however, the current delivery of allied
healthcare services is inadequate, and many people who
require such care are not being referred to the relevant spe-
cialist. Parkinson’s Standards of Care Consensus Statement
will soon be released by the European Parkinson’s Disease
Association and should be implemented in Europe in the
near future.2 Parkinson’s Disease
Besides symptomatic treatment, search for the disease-
modifying, neuroprotective, and restorative treatment of PD
is ongoing. Despite many so far unresolved issues, gene-
and stem-cell-based therapies as well as immunotherapy
targeting alpha-synuclein might become treatment options
in the future. Development of these therapies is dependent
on an accurate and comprehensive understanding of the
pathogenesis and pathophysiology of PD and on the ability
of very early diagnosis of premotor stages of PD. Therefore,
a search for speciﬁc biomarkers (clinical, neuroimaging,
biochemical, genetic) for early (premotor) diagnosis and for
the disease progression is essential and large multicenter
trials are underway.
This special issue is dedicated to nonmotor symptoms of
PD and focuses on the above-mentioned “old-new” topics.
Wesincerelyhopethatitwillprovidereaderswithinteresting
new data as well as with comprehensive up-to-date reviews.
We wish our readers pleasant and inspiring reading.
Irena Rektorova
Dag Aarsland
K. Ray Chaudhuri
Antonio P. Strafella
References
[1] P. Barone, A. Antonini, C. Colosimo et al., “The PRIAMO
study: a multicenter assessment of nonmotor symptoms and
theirimpactonqualityoflifeinParkinson’sdisease,”Movement
Disorders, vol. 24, no. 11, pp. 1641–1649, 2009.
[2] K. R. Chaudhuri, C. Prieto-Jurcynska, Y. Naidu et al., “The
nondeclaration of nonmotor symptoms of Parkinson’s disease
to health care professionals: an international study using the
nonmotor symptoms questionnaire,” Movement Disorders, vol.
25, no. 6, pp. 697–701, 2010.
[3] K. R. Chaudhuri and A. H. Schapira, “Non-motor symptoms
of Parkinson’s disease: dopaminergic pathophysiology and
treatment,” The Lancet Neurology, vol. 8, no. 5, pp. 464–474,
2009.
[4] H. Braak, K. del Tredici, U. R¨ u b ,R .A .I .d eV o s ,E .N .H .
Jansen Steur, and E. Braak, “Staging of brain pathology related
to sporadic Parkinson’s disease,” Neurobiology of Aging, vol. 24,
no. 2, pp. 197–211, 2003.
[5] G. Halliday, M. Hely, W. Reid, and J. Morris, “The progression
of pathology in longitudinally followed patients with Parkin-
son’s disease,” Acta Neuropathologica, vol. 115, no. 4, pp. 409–
415, 2008.
[6] D. Aarsland, U. Ehrt, and I. Rektorova, “Cognitive and psychi-
atric disturbances in Parkinsons disease,” Aging Health, vol. 7,
no. 1, pp. 123–142, 2011.
[7] M. A. Hely, W. G. J. Reid, M. A. Adena, G. M. Halliday, and
J. G. L. Morris, “The Sydney Multicenter Study of Parkinson’s
disease: the inevitability of dementia at 20 years,” Movement
Disorders, vol. 23, no. 6, pp. 837–844, 2008.
[8] A. L. Benabid, S. Chabardes, J. Mitrofanis, and P. Pollak, “Deep
brain stimulation of the subthalamic nucleus for the treatment
of Parkinson’s disease,” The Lancet Neurology,v o l .8 ,n o .1 ,p p .
67–81, 2009.
[9] A. J. Lees, J. Hardy, and T. Revesz, “Parkinson’s disease,” The
Lancet, vol. 373, no. 9680, pp. 2055–2066, 2009.